Skip to main content
Equibles
XAIR logo

XAIR · Beyond Air, Inc. · Metrics

Track XAIR — free

Use XAIR with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research XAIR.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.16 -0.02 (-0.92%) At close · Nov 6 Play latest call Q4 2026 earnings call transcript
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Management believes these factors raise substantial doubt about the Company's ability to meet its obligations with cash on hand and concluded that the Company will require additional funding within one year from the date these financial statements are issued. Management is confident that the efforts to arrange financing, while not assured, will enable them to meet the Company's obligations.”
View the 10-Q filed Aug 13, 2026
Market Cap
$2.07M
Shares
957,631
Volume · Nov 6 17.59K Avg daily vol (3M) 212.99K

XAIR metrics

65 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$2.16
Market cap
$2.07M

Price action

23 metrics
Price change (1W)
-5.6%
Price change (30D)
-14.2%
Price change (3M)
-60.8%
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
105.8%
Annualized volatility (3M)
98.8%
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
—
RSI (14D)
39.1
Price vs SMA 50
-22.7%
Price vs SMA 200
—
Avg volume (3M)
213,051
Relative volume
0.1
Average dollar volume
$848,394

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
957,631

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
0.3×
reciprocal yield 368.2%
P / book
1.0
reciprocal yield 95.7%
FCF yield
-938.8%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-1,589.1%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
11.9×
reciprocal yield 8.4%
EV / revenue historical average (5Y)
53.5×
reciprocal yield 1.9%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-18

Profitability

9 metrics
Gross margin
4.2%
Operating margin
-364.8%
Trailing 12 months
Net margin
-431.6%
Gross profit (TTM)
$321,000
Operating profit (TTM)
−$28.04M
Net income (TTM)
−$33.17M
Trailing 12 months
Diluted EPS (TTM)
$-60.53
FCF margin
-255.0%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$10.39

Growth

11 metrics
Revenue growth YoY
+0.5%
Year over year
Net income growth YoY
—
Revenue (TTM)
$7.69M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+187.7%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
+54.5%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-1,661.2%
Return on assets
-100.9%
Debt / equity
—
Current ratio
3.3
EBITDA (TTM)
−$24.94M
Free cash flow (TTM)
−$19.60M
Quick ratio
3.1
Interest coverage
-6.3
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$5.51M
Total assets
$32.89M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$18.56M
Capital expenditures (TTM)
$1.03M
R&D (TTM)
$9.11M
SG&A (TTM)
$19.25M
Stock compensation (TTM)
$4.74M
R&D / revenue
118.6%
Stock compensation / revenue
61.7%

Ownership (13F)

9 metrics
13F filers
29
13F filer change QoQ
0
Institutional ownership
7.2%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
6.1%
Private-fund adviser ownership
5.8%
Active holders' share change QoQ
-1.4%
Holder tenure
6.7
Price vs estimated holder cost
-58.5%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.3%

Short interest

3 metrics
Short interest
6.2%
Latest settlement · 1.3 days to cover
Days to cover
1.3d
Short-squeeze score
49 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1641631 CUSIP 08862L301 13F (30d) 13 filings 6 filers Visit website Investor relations